A bdominal aortic aneurysm (AAA) is a potentially lethal condition, capable of progressing to acute rupture-a cat astrophic event with an 80% mortality risk. A conservative esti mate places annual deaths because of AAA in the United States at ≈15 000, although the actual burden is likely higher. 1 These dilations are typically found within the infrarenal aortic seg ment but are only rarely symptomatic, causing them to remain undiscovered until they are either identified through coincident imaging or rupture occurs. Among the risk factors for AAA are male sex, advanced age, genetic predilection, and a history of tobacco use. No pharmacological approach in humans to date has successfully decreased AAA expansion or prevented rupture. 2 Although surgery and endovascular stent grafting are highly effective in preventing death from larger AAAs, they are complex procedures with multiple potential complications. How then, might the battle against AAA be better waged?
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MicroRNAs are intricately woven into a web of epigenetic pathophysiologic regulation. Modulation of any given micro RNA can alter the expression of dozens of target genes, in cluding entire functional gene networks, thereby affecting the progression of a wide array of disease phenotypes. In recent reviews examining the role of microRNAs in AAA, we noted their remarkable potential, both to improve risk stratification and diagnosis and to alter vascular disease therapeutically. In this vein, exciting findings have been published for several mi croRNAs including miR21, miR26a, the miR1792cluster, miRs221/222, miR133, miR126, miR143/145, miR146a, miR155, and miR29b. 3, 4 Of these candidates, the last (miR29b) seems particularly promising. Remodeling of the extracellular matrix within the aortic adventitia and media is crucial for AAA progression, characterized by elastin fragmentation and loss and increased collagen turnover. miR29b targets include numerous collagen genes and elastin. Furthermore, miR29b modulation in vitro and in vivo can alter matrix metalloprotease (MMP) activity. miR29b is differentially regulated in animal models of aneu rysm and in human AAA tissue, and inhibition of miR29b in murine models of AAA and Marfan syndrome has led to diminished aneurysm progression (while overexpression in creases aneurysm growth and rupture rate). [5] [6] [7] In this issue of Circulation Research, Zampetaki et al ex amined miR195, a member of the miR15 family known to share many of the same targets as miR29b. 8, 9 They found that miR195 (alone of the miR15 family) was increased in aneurysmal aortic tissue from angiotensin II-treated apolipo protein E-deficient mice. Angiotensin II has previously been shown to induce or inhibit miR15a, 15b, 161, and 162 in either rat or human smooth muscle cells, but not miR195. 10, 11 Furthermore, although significant downregulation of miR15a, miR195, and miR497 has been observed in tissue from dis sected human thoracic aorta compared with normal aorta, Pahl et al's expression profiling of human AAA tissue did not iden tify any differentially regulated miR15 family members. 12, 13 In human aortic smooth muscle cells, miR195 mimic was able to suppress elastin expression, but unlike miR29b, caused a nonsignificant increase in MMP9 activity and an in crease in MMP2 expression. The authors then performed pro teomic studies of human smooth muscle cells, confirming that miR195 regulates numerous extracellular matrix elements, although not to the same extent as miR29b (especially in terms of collagen repression).
More disappointing were attempts at in vivo inhibition of miR195 in the mouse AAA model. Although clear suppres sion of miR195 in the aorta was achieved, correlating with increases in expression of elastin and collagens, there was no significant impact on aneurysm progression or subject surviv al (no in vivo miR195mimic experiments were performed). Immunohistochemistry showed increased Mmp9 expression in antimiR195-transfected aortae. In contrast, and confirm ing published data using the same model, antimiR29b led to improved survival and slowed aortic growth. Maegdefessel et al 7 also demonstrated that systemic antimiR29b lowered MMP2 and MMP9 activity and expression in vivo.
Zampetaki et al 9 noted that antagomiR29b had minimal effects on miR29b levels in an aortic isograft model. This supports the conclusion in Maegdefessel et al 7 that locked nucleic acid (LNA)antimiR29b is not readily taken up by uninjured vessel wall. However, in both studies, uptake within the affected suprarenal aorta (angiotensin II murine model) was sufficient to alter disease progression and target expression. In contrast, antimiR195 diffused more readily into uninjured vasculature but did not abrogate disease. This is unusual, as in our experience intact endothelium often re sists LNAmiR uptake. The authors attribute the contrasting in vivo results between antimiR195 and antimiR29b to their inverse regulatory effects on MMP activity. Given the known association between MMP activity and AAA severity and progression, this may well be the case. 14
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Interestingly, in addition to its role in extracellular matrix regulation, miR195 is a known tumor suppressor, which has been shown to inhibit growth and proliferation, promote apop tosis, and inhibit cellular migration in various tissues and cell types. 15 In contrast another microRNA-miR21-inhibits tu mor suppressors, eliciting the opposite cellular responses from those attributed to miR195, and premiR21 administration has significantly curtailed murine AAA growth. 16 It might have been expected that antimiR195 would, therefore, have simi lar effects. However, miR195 is also known to suppress an giogenesis. 17 Angiogenesis inhibition is believed to limit AAA progression, which might, therefore, have further undermined the effectiveness of antimiR195. 18 Zampetaki et al 9 also suggest an intriguing role for miR 195 as an AAA biomarker, which miR29b is unlikely to match (as it was barely detectable in human plasma samples). Circulating microRNAs are stable in human blood and de tectable and measurable with high sensitivity and specificity, suggesting that they might make effective AAA biomark ers. 19, 20 Clinical studies have demonstrated changes in mi croRNA levels in association with cardiovascular disease phenotypes, although these have often been underpowered or lacking in matched controls. 21, 22 The authors examined 16 mi croRNAs in plasma from 73 participants from an aneurysm screening program, finding that miR195 was inversely corre lated with aneurysm size and disease classification. Although 4 other miRs also showed such association, they were closely correlated with miR195, and after proper adjustment their association with aortic size diminished. Intriguingly, miR 133a and miR145 emerged as significant after adjustment for miR195, suggesting that further studies involving a com bination approach might yield a robust biomarker panel. As in the work cited above, the sample size queried was small for a biomarker study, and these findings will require extensive verification and replication in larger data sets to prove clini cal utility.
Despite the similar target profiles of miR29b and miR195, it remains to be seen whether the first may someday triumph on the field of therapeutic AAA abrogation and whether the latter will fulfill its promise as a predictive biomarker of AAA progression.
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